Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?

Acheampong E, Spencer I, Lin W, Ziman M, Millward M, Gray E.

Cancers (Basel). 2019 Jun 30;11(7). pii: E920. doi: 10.3390/cancers11070920. Review.

2.

Investigating the relationships between hypothalamic volume and measures of circadian rhythm and habitual sleep in premanifest Huntington's disease.

Bartlett DM, Domínguez D JF, Reyes A, Zaenker P, Feindel KW, Newton RU, Hannan AJ, Slater JA, Eastwood PR, Lazar AS, Ziman M, Cruickshank T.

Neurobiol Sleep Circadian Rhythms. 2018 Jul 3;6:1-8. doi: 10.1016/j.nbscr.2018.07.001. eCollection 2019 Jan.

3.

Optimal Probabilistic Storage and Retrieval of Unitary Channels.

Sedlák M, Bisio A, Ziman M.

Phys Rev Lett. 2019 May 3;122(17):170502. doi: 10.1103/PhysRevLett.122.170502.

PMID:
31107082
4.

Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome.

Osborne DG, Domenico J, Luo Y, Reid AL, Amato C, Zhai Z, Gao D, Ziman M, Dinarello CA, Robinson WA, Fujita M.

Mol Carcinog. 2019 May 16. doi: 10.1002/mc.23044. [Epub ahead of print]

PMID:
31099111
5.

Determinants for concomitant anxiety and depression in people living with chronic obstructive pulmonary disease.

Phan T, Carter O, Waterer G, Chung LP, Hawkins M, Rudd C, Ziman M, Strobel N.

J Psychosom Res. 2019 May;120:60-65. doi: 10.1016/j.jpsychores.2019.03.004. Epub 2019 Mar 8.

PMID:
30929709
6.

Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles.

Aya-Bonilla C, Gray ES, Manikandan J, Freeman JB, Zaenker P, Reid AL, Khattak MA, Frank MH, Millward M, Ziman M.

Cancers (Basel). 2019 Jan 30;11(2). pii: E157. doi: 10.3390/cancers11020157.

7.

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

Gray ES, Witkowski T, Pereira M, Calapre L, Herron K, Irwin D, Chapman B, Khattak MA, Raleigh J, Hatzimihalis A, Cebon J, Sandhu S, McArthur GA, Millward M, Ziman M, Dobrovic A, Wong SQ.

J Mol Diagn. 2019 May;21(3):418-426. doi: 10.1016/j.jmoldx.2018.12.001. Epub 2019 Feb 5.

PMID:
30731208
8.

Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies.

McEvoy AC, Pereira MR, Reid A, Pearce R, Cowell L, Al-Ogaili Z, Khattak MA, Millward M, Meniawy TM, Gray ES, Ziman M.

Oncotarget. 2019 Jan 4;10(2):113-122. doi: 10.18632/oncotarget.26451. eCollection 2019 Jan 4.

9.

Prognostic Relevance of CCDC88C (Daple) Transcripts in the Peripheral Blood of Patients with Cutaneous Melanoma.

Dunkel Y, Reid AL, Ear J, Aznar N, Millward M, Gray E, Pearce R, Ziman M, Ghosh P.

Sci Rep. 2018 Dec 21;8(1):18036. doi: 10.1038/s41598-018-36173-x.

10.

Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma.

Calapre L, Giardina T, Robinson C, Reid AL, Al-Ogaili Z, Pereira MR, McEvoy AC, Warburton L, Hayward NK, Khattak MA, Meniawy TM, Millward M, Amanuel B, Ziman M, Gray ES.

Mol Oncol. 2019 Feb;13(2):171-184. doi: 10.1002/1878-0261.12391. Epub 2018 Dec 7.

11.

Computerised Dynamic Posturography in Premanifest and Manifest individuals with Huntington's Disease.

Reyes A, Salomonczyk D, Teo WP, Medina LD, Bartlett D, Pirogovsky-Turk E, Zaenker P, Bloom JC, Simmons RW, Ziman M, Gilbert PE, Cruickshank T.

Sci Rep. 2018 Oct 2;8(1):14615. doi: 10.1038/s41598-018-32924-y.

12.

A diagnostic autoantibody signature for primary cutaneous melanoma.

Zaenker P, Lo J, Pearce R, Cantwell P, Cowell L, Lee M, Quirk C, Law H, Gray E, Ziman M.

Oncotarget. 2018 Jul 17;9(55):30539-30551. doi: 10.18632/oncotarget.25669. eCollection 2018 Jul 17.

13.

Effects of multidisciplinary therapy on physical function in Huntington's disease.

Cruickshank TM, Reyes AP, Penailillo LE, Pulverenti T, Bartlett DM, Zaenker P, Blazevich AJ, Newton RU, Thompson JA, Lo J, Ziman MR.

Acta Neurol Scand. 2018 Dec;138(6):500-507. doi: 10.1111/ane.13002. Epub 2018 Jul 30.

PMID:
30058184
14.

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.

McEvoy AC, Warburton L, Al-Ogaili Z, Celliers L, Calapre L, Pereira MR, Khattak MA, Meniawy TM, Millward M, Ziman M, Gray ES.

BMC Cancer. 2018 Jul 9;18(1):726. doi: 10.1186/s12885-018-4637-6.

15.

Melanoma circulating tumor cells: Benefits and challenges required for clinical application.

Marsavela G, Aya-Bonilla CA, Warkiani ME, Gray ES, Ziman M.

Cancer Lett. 2018 Jun 28;424:1-8. doi: 10.1016/j.canlet.2018.03.013. Epub 2018 Mar 14. Review.

16.

The validity and reliability of using ultrasound elastography to measure cutaneous stiffness, a systematic review.

DeJong HM, Abbott S, Zelesco M, Kennedy BF, Ziman MR, Wood FM.

Int J Burns Trauma. 2017 Dec 20;7(7):124-141. eCollection 2017. Review.

17.

Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing.

McEvoy AC, Wood BA, Ardakani NM, Pereira MR, Pearce R, Cowell L, Robinson C, Grieu-Iacopetta F, Spicer AJ, Amanuel B, Ziman M, Gray ES.

J Mol Diagn. 2018 Mar;20(2):240-252. doi: 10.1016/j.jmoldx.2017.11.009. Epub 2018 Jan 2.

PMID:
29305225
18.

Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma.

McEvoy AC, Calapre L, Pereira MR, Giardina T, Robinson C, Khattak MA, Meniawy TM, Pritchard AL, Hayward NK, Amanuel B, Millward M, Ziman M, Gray ES.

Oncotarget. 2017 Aug 18;8(45):78890-78900. doi: 10.18632/oncotarget.20354. eCollection 2017 Oct 3.

19.

Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device.

Aya-Bonilla CA, Marsavela G, Freeman JB, Lomma C, Frank MH, Khattak MA, Meniawy TM, Millward M, Warkiani ME, Gray ES, Ziman M.

Oncotarget. 2017 Jun 27;8(40):67355-67368. doi: 10.18632/oncotarget.18641. eCollection 2017 Sep 15.

20.

Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.

Calapre L, Warburton L, Millward M, Ziman M, Gray ES.

Cancer Lett. 2017 Sep 28;404:62-69. doi: 10.1016/j.canlet.2017.06.030. Epub 2017 Jul 4. Review.

21.

SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes.

Calapre L, Gray ES, Kurdykowski S, David A, Descargues P, Ziman M.

BMC Dermatol. 2017 Jun 10;17(1):8. doi: 10.1186/s12895-017-0060-y.

22.

Neuroendocrine and neurotrophic signaling in Huntington's disease: Implications for pathogenic mechanisms and treatment strategies.

Bartlett DM, Cruickshank TM, Hannan AJ, Eastwood PR, Lazar AS, Ziman MR.

Neurosci Biobehav Rev. 2016 Dec;71:444-454. doi: 10.1016/j.neubiorev.2016.09.006. Epub 2016 Sep 13. Review.

23.

Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo.

Calapre L, Gray ES, Kurdykowski S, David A, Hart P, Descargues P, Ziman M.

BMC Dermatol. 2016 May 26;16(1):6. doi: 10.1186/s12895-016-0043-4.

24.

Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression and anxiety in patients with chronic obstructive pulmonary disease.

Phan T, Carter O, Adams C, Waterer G, Chung LP, Hawkins M, Rudd C, Ziman M, Strobel N.

Chron Respir Dis. 2016 Aug;13(3):220-8. doi: 10.1177/1479972316634604. Epub 2016 Mar 3.

25.

Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients.

Zaenker P, Gray ES, Ziman MR.

Autoimmun Rev. 2016 May;15(5):477-83. doi: 10.1016/j.autrev.2016.01.017. Epub 2016 Jan 28. Review.

26.

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.

Gray ES, Rizos H, Reid AL, Boyd SC, Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, Siew K, Lomma C, Cooper A, Khattak MA, Meniawy TM, Long GV, Carlino MS, Millward M, Ziman M.

Oncotarget. 2015 Dec 8;6(39):42008-18. doi: 10.18632/oncotarget.5788.

27.

Novel Nut and Bolt Task Quantifies Motor Deficits in Premanifest and Manifest Huntington's Disease.

Collins LM, Begeti F, Panin F, Lazar AS, Cruickshank T, Ziman M, Mason SL, Barker RA.

PLoS Curr. 2015 Sep 8;7. pii: ecurrents.hd.ded251617ae62a1364506b0521bd3761. doi: 10.1371/currents.hd.ded251617ae62a1364506b0521bd3761.

28.

Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells.

Bartlett D, Boyle GM, Ziman M, Medic S.

PLoS One. 2015 Apr 16;10(4):e0124154. doi: 10.1371/journal.pone.0124154. eCollection 2015.

29.

Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.

Gray ES, Reid AL, Bowyer S, Calapre L, Siew K, Pearce R, Cowell L, Frank MH, Millward M, Ziman M.

J Invest Dermatol. 2015 Aug;135(8):2040-2048. doi: 10.1038/jid.2015.127. Epub 2015 Apr 1.

30.

The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study.

Cruickshank TM, Thompson JA, Domínguez D JF, Reyes AP, Bynevelt M, Georgiou-Karistianis N, Barker RA, Ziman MR.

Brain Behav. 2015 Feb;5(2):e00312. doi: 10.1002/brb3.312. Epub 2015 Jan 15.

31.

A systematic review and meta-analysis of strength training in individuals with multiple sclerosis or Parkinson disease.

Cruickshank TM, Reyes AR, Ziman MR.

Medicine (Baltimore). 2015 Jan;94(4):e411. doi: 10.1097/MD.0000000000000411. Review.

32.

Respiratory muscle training on pulmonary and swallowing function in patients with Huntington's disease: a pilot randomised controlled trial.

Reyes A, Cruickshank T, Nosaka K, Ziman M.

Clin Rehabil. 2015 Oct;29(10):961-73. doi: 10.1177/0269215514564087. Epub 2014 Dec 31.

PMID:
25552526
33.

Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.

Reid AL, Freeman JB, Millward M, Ziman M, Gray ES.

Clin Biochem. 2015 Oct;48(15):999-1002. doi: 10.1016/j.clinbiochem.2014.12.007. Epub 2014 Dec 16.

PMID:
25523300
34.

Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma.

Klinac D, Gray ES, Freeman JB, Reid A, Bowyer S, Millward M, Ziman M.

BMC Cancer. 2014 Jun 11;14:423. doi: 10.1186/1471-2407-14-423.

35.

Pulmonary function in patients with Huntington's disease.

Reyes A, Cruickshank T, Ziman M, Nosaka K.

BMC Pulm Med. 2014 May 26;14:89. doi: 10.1186/1471-2466-14-89.

36.

Pax genes: regulators of lineage specification and progenitor cell maintenance.

Blake JA, Ziman MR.

Development. 2014 Feb;141(4):737-51. doi: 10.1242/dev.091785. Review.

37.

Surface electromyograph activity of submental muscles during swallowing and expiratory muscle training tasks in Huntington's disease patients.

Reyes A, Cruickshank T, Thompson J, Ziman M, Nosaka K.

J Electromyogr Kinesiol. 2014 Feb;24(1):153-8. doi: 10.1016/j.jelekin.2013.09.009. Epub 2013 Oct 16.

PMID:
24182734
38.

Melanoma biomolecules: independently identified but functionally intertwined.

Dye DE, Medic S, Ziman M, Coombe DR.

Front Oncol. 2013 Sep 24;3:252. doi: 10.3389/fonc.2013.00252. Review.

39.

Serologic autoantibodies as diagnostic cancer biomarkers--a review.

Zaenker P, Ziman MR.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2161-81. doi: 10.1158/1055-9965.EPI-13-0621. Epub 2013 Sep 20. Review.

40.

Heat stress: a risk factor for skin carcinogenesis.

Calapre L, Gray ES, Ziman M.

Cancer Lett. 2013 Aug 28;337(1):35-40. doi: 10.1016/j.canlet.2013.05.039. Epub 2013 Jun 5. Review.

PMID:
23748013
41.

Respiratory muscle training for respiratory deficits in neurodegenerative disorders: a systematic review.

Reyes A, Ziman M, Nosaka K.

Chest. 2013 May;143(5):1386-1394. doi: 10.1378/chest.12-1442. Review.

PMID:
23714850
42.

The characterisation of Pax3 expressant cells in adult peripheral nerve.

Blake JA, Ziman MR.

PLoS One. 2013;8(3):e59184. doi: 10.1371/journal.pone.0059184. Epub 2013 Mar 19.

43.

Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.

Klinac D, Gray ES, Millward M, Ziman M.

Front Oncol. 2013 Mar 19;3:54. doi: 10.3389/fonc.2013.00054. eCollection 2013.

44.

The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study.

Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA, Ziman MR.

Eur J Neurol. 2013 Sep;20(9):1325-9. doi: 10.1111/ene.12053. Epub 2012 Dec 7.

PMID:
23216520
45.

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.

Reid AL, Millward M, Pearce R, Lee M, Frank MH, Ireland A, Monshizadeh L, Rai T, Heenan P, Medic S, Kumarasinghe P, Ziman M.

Br J Dermatol. 2013 Jan;168(1):85-92. doi: 10.1111/bjd.12057. Epub 2012 Nov 15.

46.

Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells.

Freeman JB, Gray ES, Millward M, Pearce R, Ziman M.

J Transl Med. 2012 Sep 15;10:192. doi: 10.1186/1479-5876-10-192.

47.

PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.

Charytonowicz E, Matushansky I, Doménech JD, Castillo-Martín M, Ladanyi M, Cordon-Cardo C, Ziman M.

Clin Transl Oncol. 2012 Mar;14(3):197-206.

PMID:
22374423
48.

Pax genes during neural development and their potential role in neuroregeneration.

Thompson JA, Ziman M.

Prog Neurobiol. 2011 Nov;95(3):334-51. doi: 10.1016/j.pneurobio.2011.08.012. Epub 2011 Sep 14. Review.

PMID:
21930183
49.

WITHDRAWN: Pax genes during neural development and their potential role in neuroregeneration.

Thompson JA, Ziman M.

Brain Res. 2011 May 12. [Epub ahead of print]

PMID:
21851930
50.

The pharmacists' role in improving guideline compliance for thyroid function testing in patients with heart failure.

Ziman ME, Bui HT, Smith CS, Tsukiji LA, Asmatey VM, Chu SB, Miano JS.

J Pharm Pract. 2012 Apr;25(2):195-200. doi: 10.1177/0897190011416008. Epub 2011 Aug 15.

PMID:
21844214

Supplemental Content

Support Center